AntiHER2

Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad…

Both tucatinib (Tukysa) and trastuzumab deruxtecan (Enhertu) have been shown to be highly efficacious in the pivotal HER2CLIMB and DESTINY-Breast01 trials,…